Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $26.3 million.

  • Madrigal Pharmaceuticals' Share-based Compensation rose 4667.56% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.0 million, marking a year-over-year increase of 1682.15%. This contributed to the annual value of $79.9 million for FY2024, which is 6061.12% up from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' Share-based Compensation stood at $26.3 million, which was up 4667.56% from $25.2 million recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Share-based Compensation peaked at $26.3 million during Q3 2025, and registered a low of $6.1 million during Q1 2021.
  • In the last 5 years, Madrigal Pharmaceuticals' Share-based Compensation had a median value of $11.2 million in 2023 and averaged $13.7 million.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Share-based Compensation plummeted by 287.32% in 2022 and then soared by 12240.04% in 2024.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Share-based Compensation stood at $6.4 million in 2021, then increased by 27.16% to $8.1 million in 2022, then soared by 83.77% to $14.9 million in 2023, then rose by 19.01% to $17.7 million in 2024, then surged by 48.52% to $26.3 million in 2025.
  • Its Share-based Compensation stands at $26.3 million for Q3 2025, versus $25.2 million for Q2 2025 and $20.9 million for Q1 2025.